Financial News
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - June 18, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against ACADIA
Pharmaceuticals Inc. (“Acadia” or “the Company”) (NASDAQ: ACAD) for
violations of §§10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
Investors who
purchased the Company's securities between June 15, 2020 and April 4, 2021,
inclusive (the ''Class Period''), are encouraged to contact the firm before June
18, 2021.
If you are a
shareholder who suffered a loss, click here to participate.
We also encourage you
to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite
2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of
charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this
case, has not yet been certified, and until certification occurs, you are not
represented by an attorney. If you choose to take no action, you can remain an
absent class member.
According to the
Complaint, the Company made false and misleading statements to the market.
Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design
and statistical problems. The pimavanserin sNDA did not contain the support for
its approval despite the Company telling investors that it did. As a result,
the FDA was unlikely to approve the sNDA as it was submitted. Based on these
facts, the Company’s public statements were false and materially misleading
throughout the class period. When the market learned the truth about Acadia,
investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm
represents investors around the world and specializes in securities class
action lawsuits and shareholder rights litigation.
This press release may
be considered Attorney Advertising in some jurisdictions under the applicable
law and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.